Re: Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
This is a valid scientific question that is being assessed in the medical literature and apparently by the FDA and European Medicines Agency. The diabetes community is in the inter-regnum between the launch of a new class of drugs and hard end-point data that will clarify the risk:benefit ratios in different classes of patients.
However I really think the style of this article is not appropriate. The tone is that of a detective investigating a conspiracy which includes the regulators. Thus meetings are repeatedly described as 'closed door'.
BMJ should have a different style to Despatches.
Competing interests: No competing interests